MRK reports that 44% and 46% of patients in the Boceprevir SPRINT-2 and RESPOND-2 studies, respectively, stopped treatment early according to the response-guided protocol in these studies:
Early response-guided stopping occurred after 28 weeks in the SPRINT-2 study in the first-line setting (which included a 4-week lead-in period on SoC only) and after 36 weeks in the RESPOND-2 study in the second-line (for non-null-responders in the first line).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.